Cyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded to “Sell” at StockNews.com

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Separately, Roth Mkm lowered their target price on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating for the company in a report on Friday, May 3rd.

Cyclacel Pharmaceuticals Stock Performance

CYCC stock traded down $0.20 during trading on Thursday, hitting $1.70. 139,044 shares of the company’s stock traded hands, compared to its average volume of 527,721. Cyclacel Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $13.20. The business has a fifty day simple moving average of $2.01 and a 200 day simple moving average of $2.34. The stock has a market capitalization of $2.48 million, a price-to-earnings ratio of -0.08 and a beta of 0.58.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.93) by $2.66. The firm had revenue of $0.03 million during the quarter. Cyclacel Pharmaceuticals had a negative net margin of 4,401.34% and a negative return on equity of 1,009.04%. During the same quarter last year, the business posted ($7.05) EPS. Research analysts forecast that Cyclacel Pharmaceuticals will post -4.93 earnings per share for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.